Physician profile
Beiqing Pan
NPI 1881910263
$871.99
in general payments reported to CMS, 2019-2025
23 companies · $353 in 2025
The $353 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.37 · 2020: $24.53 · 2021: $11.92 · 2023: $317 · 2024: $152 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.11 |
| Education | $186.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $177.01 | 2023-2025 | Enhertu, Datroway |
| Ambu INC. | $117.87 | 2023 | |
| Novartis Pharmaceuticals Corporation | $59.38 | 2023-2025 | |
| Abbvie INC. | $54.02 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $51.06 | 2024 | Libtayo |
| Glaxosmithkline, LLC. | $49.43 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Exelixis INC. | $37.27 | 2025 | Cabometyx |
| Puma Biotechnology, INC. | $32.98 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $32.10 | 2019-2023 | Keytruda |
| Pfizer INC. | $31.84 | 2020-2023 | |
| Gilead Sciences, INC. | $29.94 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $29.01 | 2023 | |
| Pharmacosmos Therapeutics INC. | $20.96 | 2025 | Monoferric |
| Mirati Therapeutics, INC. | $20.47 | 2024 | Krazati |
| Genentech USA, INC. | $19.83 | 2023 | Polivy, Lunsumio, Columvi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $18.00 | 2025 | |
| Incyte Corporation | $16.91 | 2024 | Jakafi |
| Astellas Pharma US INC | $16.65 | 2023 | Padcev |
| Alexion Pharmaceuticals, INC. | $15.83 | 2023 | Ultomiris |
| Celgene Corporation | $14.64 | 2024 | Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $14.22 | 2024 | Krazati |
| Karyopharm Therapeutics INC. | $12.57 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beiqing Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.